DK2531221T3 - Polyanioniske multivalente makromolekyler til intracellulær målretning af proliferation og proteinsyntese - Google Patents
Polyanioniske multivalente makromolekyler til intracellulær målretning af proliferation og proteinsyntese Download PDFInfo
- Publication number
- DK2531221T3 DK2531221T3 DK11701951.3T DK11701951T DK2531221T3 DK 2531221 T3 DK2531221 T3 DK 2531221T3 DK 11701951 T DK11701951 T DK 11701951T DK 2531221 T3 DK2531221 T3 DK 2531221T3
- Authority
- DK
- Denmark
- Prior art keywords
- polyanional
- makromolecules
- multivalent
- proliferation
- protein synthesis
- Prior art date
Links
- 230000003834 intracellular effect Effects 0.000 title 1
- 230000035755 proliferation Effects 0.000 title 1
- 238000001243 protein synthesis Methods 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 230000014616 translation Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
- A61K49/124—Macromolecular compounds dendrimers, dendrons, hyperbranched compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
- A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/14—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
- C08G83/002—Dendritic macromolecules
- C08G83/003—Dendrimers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Radiology & Medical Imaging (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Polymers & Plastics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Polyethers (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10001104 | 2010-02-03 | ||
EP10001655 | 2010-02-18 | ||
EP10002121 | 2010-03-02 | ||
PCT/EP2011/000425 WO2011095311A1 (en) | 2010-02-03 | 2011-01-31 | Polyanionic multivalent macromolecules for intracellular targeting of proliferation and protein synthesis |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2531221T3 true DK2531221T3 (da) | 2019-06-17 |
Family
ID=43981117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11701951.3T DK2531221T3 (da) | 2010-02-03 | 2011-01-31 | Polyanioniske multivalente makromolekyler til intracellulær målretning af proliferation og proteinsyntese |
Country Status (13)
Country | Link |
---|---|
US (1) | US8877171B2 (da) |
EP (1) | EP2531221B1 (da) |
JP (2) | JP5866301B2 (da) |
CN (1) | CN102781478A (da) |
AU (1) | AU2011212742B2 (da) |
BR (1) | BR112012019520A2 (da) |
CA (1) | CA2788736C (da) |
DK (1) | DK2531221T3 (da) |
ES (1) | ES2730744T3 (da) |
HU (1) | HUE045311T2 (da) |
NZ (1) | NZ601550A (da) |
PL (1) | PL2531221T3 (da) |
WO (1) | WO2011095311A1 (da) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2014051109A1 (ja) * | 2012-09-28 | 2016-08-25 | 協和発酵キリン株式会社 | 抗ヒトbmp9抗体および該抗体を有効成分とする異所性骨化疾患の治療剤 |
CN104995201B (zh) * | 2013-01-23 | 2017-12-22 | 北京市丰硕维康技术开发有限责任公司 | 一种治疗肿瘤细胞增生性疾病的铂(ii)类化合物 |
EP2923695A1 (en) | 2014-03-25 | 2015-09-30 | DendroPharm GmbH | Hyperbranched polyglycerol sulfates with hydrophobic cores |
JPWO2015170573A1 (ja) * | 2014-05-08 | 2017-04-20 | 公立大学法人大阪府立大学 | リンパ節イメージング剤 |
EP3142641B1 (de) | 2014-05-13 | 2020-11-25 | DendroPharm GmbH | Formulierungen zur behandlung von hyperthyreose |
WO2015177279A1 (en) | 2014-05-21 | 2015-11-26 | Ic Discovery Gmbh | Therapeutic conjugates with sulfated dendrimers for intracellular targeting |
EP3048130A1 (en) | 2015-01-20 | 2016-07-27 | Freie Universität Berlin | Anionic linear polyglycerol derivatives, a method for manufacturing and applications |
WO2016166317A1 (en) * | 2015-04-15 | 2016-10-20 | Freie Universität Berlin | Polyglycerol derivative and a method for manufacturing the same |
DE102015121366A1 (de) | 2015-12-08 | 2017-06-08 | Dendropharm Gmbh | Analgetische Zusammensetzungen mit Nanocarriern und ihre Verwendung |
WO2018011209A1 (en) | 2016-07-13 | 2018-01-18 | Freie Universität Berlin | Polyglycerol derivative for use in diagnosing a disease at an early stage |
EP4134073A1 (en) | 2021-08-11 | 2023-02-15 | HM HerbaMedica GmbH | Pharmaceutical compositions comprising dendritic nanocarriers and cannabis active agents |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5474765A (en) | 1992-03-23 | 1995-12-12 | Ut Sw Medical Ctr At Dallas | Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells |
EP0697880B1 (en) * | 1993-05-03 | 2001-08-22 | Genentech, Inc. | Inhibition of leukocyte adhesion |
EP0804459A4 (en) | 1995-01-16 | 1999-05-26 | Commw Scient Ind Res Org | CONJUGATES THERAPEUTIC COMPOUND - FATTY ACID |
CN1093768C (zh) | 1995-01-30 | 2002-11-06 | 第一化学药品株式会社 | 诊断用标记物 |
JPH11140038A (ja) * | 1997-11-04 | 1999-05-25 | Kanebo Ltd | カルボン酸誘導体 |
JPH11246503A (ja) * | 1998-03-04 | 1999-09-14 | Sumitomo Pharmaceut Co Ltd | シクロヘキサン誘導体 |
DE10056136A1 (de) * | 2000-11-07 | 2002-05-16 | Nemod New Modalities | Verwendung von Schwangerschaftsproteinen, Liposomen, nativen Muzin-Fragmenten und Mimikry-Verbindungen zur Behandlung und Prophylaxe von entzündlichen Erkrankungen, zur Verhinderung der Metastasierung und zur Prophylaxe von Tumorerkrankungen |
CA2462261A1 (en) | 2001-10-03 | 2003-04-10 | Miravant Pharmaceuticals, Inc. | Chlorin photosensitizing agents for use in photodynamic therapy |
EP1450790A4 (en) | 2001-10-03 | 2005-10-26 | Miravant Pharm Inc | PHOTOSENSIBILIZING CARBAMATE DERIVATIVES |
DE102006036326A1 (de) * | 2006-08-03 | 2008-02-07 | Charité - Universitätsmedizin Berlin | Dendritische Polyglycerolsulfate und -sulfonate und deren Verwendung bei entzündlichen Erkrankungen |
EP2100621A1 (en) | 2008-03-10 | 2009-09-16 | mivenion GmbH | Polyether polyol dendron conjugates with effector molecules for biological targeting |
JP2011520962A (ja) | 2008-05-19 | 2011-07-21 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 新規カチオン性脂質を含む方法及び組成物 |
-
2011
- 2011-01-31 WO PCT/EP2011/000425 patent/WO2011095311A1/en active Application Filing
- 2011-01-31 HU HUE11701951A patent/HUE045311T2/hu unknown
- 2011-01-31 BR BR112012019520-4A patent/BR112012019520A2/pt not_active IP Right Cessation
- 2011-01-31 JP JP2012551541A patent/JP5866301B2/ja active Active
- 2011-01-31 PL PL11701951T patent/PL2531221T3/pl unknown
- 2011-01-31 US US13/576,779 patent/US8877171B2/en active Active
- 2011-01-31 DK DK11701951.3T patent/DK2531221T3/da active
- 2011-01-31 ES ES11701951T patent/ES2730744T3/es active Active
- 2011-01-31 EP EP11701951.3A patent/EP2531221B1/en active Active
- 2011-01-31 CN CN2011800083136A patent/CN102781478A/zh active Pending
- 2011-01-31 AU AU2011212742A patent/AU2011212742B2/en active Active
- 2011-01-31 NZ NZ601550A patent/NZ601550A/en unknown
- 2011-01-31 CA CA2788736A patent/CA2788736C/en active Active
-
2015
- 2015-10-09 JP JP2015200718A patent/JP2016026191A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP2013518841A (ja) | 2013-05-23 |
EP2531221A1 (en) | 2012-12-12 |
US8877171B2 (en) | 2014-11-04 |
AU2011212742A1 (en) | 2012-08-30 |
NZ601550A (en) | 2014-03-28 |
AU2011212742B2 (en) | 2014-09-04 |
ES2730744T3 (es) | 2019-11-12 |
BR112012019520A2 (pt) | 2018-03-13 |
EP2531221B1 (en) | 2019-03-13 |
HUE045311T2 (hu) | 2019-12-30 |
JP5866301B2 (ja) | 2016-02-17 |
PL2531221T3 (pl) | 2020-05-18 |
CA2788736A1 (en) | 2011-08-11 |
JP2016026191A (ja) | 2016-02-12 |
US20130095035A1 (en) | 2013-04-18 |
CN102781478A (zh) | 2012-11-14 |
CA2788736C (en) | 2020-03-31 |
WO2011095311A1 (en) | 2011-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2531221T3 (da) | Polyanioniske multivalente makromolekyler til intracellulær målretning af proliferation og proteinsyntese | |
DK3333188T3 (da) | Anti-NGF-antistoffer og deres anvendelse | |
DK2675827T3 (da) | Hidtil ukendte modulatorer og fremgangsmåder til anvendelse | |
DK2547771T3 (da) | Fremstilling af proteiner og polypeptider | |
DK2683406T3 (da) | Anti-cd40-antistoffer og anvendelser deraf | |
DK2794654T3 (da) | Anti-phf-tau-antistoffer og deres anvendelser | |
DK2914627T3 (da) | Anti-cd40-antistoffer og fremgangsmåder til anvendelse | |
DK3202460T3 (da) | Arylmethoxy-isoindolinderivater og sammensætninger omfattende og fremgangsmåder til anvendelser af samme | |
CL2014000096A1 (es) | Genes y proteinas para la sintesis de alcanoyl-coa | |
DK2806892T3 (da) | Kombineret terapeutisk anvendelse af antistoffer og endoglycosidaser | |
DK3238709T3 (da) | Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme | |
DK3689853T3 (da) | Fremgangsmåde til syntese af thyreoideahormonanaloger og polymorfer deraf | |
DK2606061T3 (da) | Bindingsproteiner til hepcidin | |
DK3597644T3 (da) | Kationiske aminlipider og anvendelser deraf | |
DK3415157T3 (da) | N-acyldipeptidderivater og anvendelser deraf | |
DK2624866T3 (da) | Tumorspecifikke antistoffer og anvendelser deraf | |
DK3213738T3 (da) | Sammensætninger og fremgangsmåder til målrettet termomodulering | |
DK3091034T3 (da) | Anti-CD40-antistoffer og anvendelser deraf | |
DK2691443T3 (da) | Konjugerede lipomerer og anvendelser af disse | |
DK2579877T3 (da) | Morpholinopyrimidiner og deres anvendelse til terapi | |
DK2768321T3 (da) | Fremgangsmåder og sammensætninger til induktion af mæthed | |
DK2663864T3 (da) | Fremgangsmåde til at vurdere immundiversitet og anvendelse af denne | |
DK2974732T3 (da) | Olie-ekstraheret produkt af indigo naturalis og fremgangsmåde til fremstilling og anvendelse deraf | |
DK2598457T3 (da) | Vandig opslæmning af amorf silica og fremgangsmåde til fremstilling heraf | |
DK2668210T3 (da) | Anti-kit antistoffer og anvendelser deraf |